Drug intelligence / Profile preview

clindamycin + erythromycin

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Topical, Oral, Intravenous (both Drugs Individually), But Combination Use Is Largely Topical Or For In Vitro Laboratory Diagnostic Testing
01

Overview

**Clindamycin + erythromycin** is a combination of two antibiotics, both of which are lincosamide and macrolide class antimicrobials, respectively. They inhibit bacterial protein synthesis by binding to the 50S ribosomal subunit, though at overlapping binding sites. This combination is rarely used clinically as a fixed product due to well-documented antagonism between the agents when used together. Both drugs are indicated for a variety of bacterial infections and have topical formulations for acne, but their concurrent use is typically discouraged outside of diagnostic laboratory settings (e.g., to detect inducible clindamycin resistance via D-zone tests). When tested together in laboratory diagnostics, their combination can reveal inducible resistance in organisms such as Staphylococcus aureus or beta-hemolytic streptococci, mediated by erm genes that modify the ribosomal target.

Other names
clindamycin + erythromycin
02

Targets

23S rRNA (23S ribosomal RNA)PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on clindamycin + erythromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clindamycin + erythromycin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call